| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 07/07/1999 | EP0927555A1 Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia |
| 07/07/1999 | EP0927183A1 Spirocyclic metalloprotease inhibitors |
| 07/07/1999 | EP0927161A1 Substituted cyclic amine metalloprotease inhibitors |
| 07/07/1999 | EP0927156A1 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| 07/07/1999 | EP0502188B1 Cloned glutamic acid decarboxylase |
| 07/06/1999 | US5919653 A recombinantly altered nucleotide sequence that codes for a neurotransmitter protein; treatment of epilepsy, stroke, multiple sclerosis, spinal cord injury, and other nervous system disorders |
| 07/01/1999 | WO1999032620A1 Insulin-like growth factor binding protein fragments and the utilization thereof |
| 07/01/1999 | WO1999016741A3 Lipophilic diesters of chelating agents |
| 07/01/1999 | DE19757250A1 Insulin-like growth factor binding protein und seine Verwendung Insulin-like growth factor binding protein and its use |
| 07/01/1999 | CA2315974A1 Insulin-like growth factor binding protein fragments and the utilization thereof |
| 06/30/1999 | EP0925298A1 Substituted 6,6-hetero-bicyclic derivatives |
| 06/30/1999 | EP0925071A1 Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions |
| 06/29/1999 | US5916887 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| 06/29/1999 | US5916878 Dipeptide of either gamma-glutamyl-l-tryptophan or beta-aspartyl-l-tryptophan; administering to the patients to reduce the risks infections from microorganism |
| 06/24/1999 | WO1999031068A1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 06/24/1999 | WO1999030687A1 Pharmaceutical compositions containing micronized bicyclic drugs |
| 06/24/1999 | CA2315079A1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 06/24/1999 | CA2314968A1 Pharmaceutical compositions containing micronized bicyclic drugs |
| 06/23/1999 | EP0923582A1 Substituted 6,5-hetero-bicyclic derivatives |
| 06/23/1999 | EP0923529A1 Subsitute 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors |
| 06/23/1999 | CN1043765C Pyrroloquinolinone derivatives, its preparing method, its intermediate and drug composition containing the same |
| 06/17/1999 | WO1999029896A1 Short gcg expansions in the pab ii gene for oculopharyngeal muscular dystrophy and diagnostic thereof |
| 06/17/1999 | WO1999029316A1 Pharmaceutical compositions containing an omega-3 fatty acid oil |
| 06/16/1999 | CN1219965A Promotion of regeneration of organized tissues |
| 06/15/1999 | US5912245 Ampa and kainate antagonists. |
| 06/15/1999 | US5912144 A polypeptide having an amino acid sequence for an immediate early response gene/g protein couplec receptor; anticarcinogenic, antiproliferative and antitumor agents |
| 06/10/1999 | WO1999028440A1 Nucleic acid encoding mammalian ubr1 |
| 06/10/1999 | WO1999028359A1 Preparation for prevention and healing of inflammation affections |
| 06/10/1999 | WO1999027890A2 A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| 06/10/1999 | CA2313243A1 Nucleic acid encoding mammalian ubr1 |
| 06/09/1999 | CN1218801A Tri-substituted imidazoles, and process of their preparation and using the same and having their pharmic composition |
| 06/09/1999 | CA2218199A1 Short gcg expansions in the pab ii gene for oculopharyngeal muscular dystrophy and diagnostic thereof |
| 06/08/1999 | US5910437 Ligated d-protein of formula r-l-r' where r and r' are peptides and l is linking group of thiol ester or selenol ester; for production of chirally pure chemicals and drugs; production of racemic crystals; prolonged half-life in body |
| 06/03/1999 | WO1999027098A2 A-33 related antigens and their pharmacological uses |
| 06/03/1999 | WO1999026962A1 Androgenic steroid compounds and a method of making and using the same |
| 06/03/1999 | WO1999026921A1 SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS |
| 06/03/1999 | WO1999026633A1 Citicoline to treat motor neuron diseases and demyelinating diseases |
| 06/03/1999 | WO1999011275A3 Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
| 06/03/1999 | CA2311448A1 Androgenic steroid compounds and a method of making and using the same |
| 06/03/1999 | CA2311422A1 Citicoline to treat motor neuron diseases and demyelinating diseases |
| 06/03/1999 | CA2309358A1 A-33 related antigens and their pharmacological uses |
| 06/03/1999 | CA2309341A1 Substituted .beta.-alanine derivatives as cell adhesion inhibitors |
| 06/02/1999 | EP0918875A1 Novel internal ribosome entry site and vector containing same |
| 06/02/1999 | EP0918758A1 Process for preparing 1-substituted 4-cyano-1,2,3-triazoles |
| 06/02/1999 | EP0918469A1 Methods and compositions for increasing the anaerobic working capacity in tissues |
| 05/27/1999 | WO1999025814A1 Genetically-modified myogenic progenitors and their use in cell and gene therapy |
| 05/27/1999 | WO1999025709A1 Isoquinoline derivatives and their therapeutical use |
| 05/27/1999 | WO1999025693A1 Metalloproteinase inhibitors |
| 05/27/1999 | WO1999014346A3 SENSE mRNA THERAPY |
| 05/27/1999 | CA2310016A1 Genetically-modified myogenic progenitors and their use in cell and gene therapy |
| 05/27/1999 | CA2309905A1 Isoquinoline derivatives and their therapeutical use |
| 05/25/1999 | US5906988 Methods of treatment using ranolazine and related piperazine derivatives |
| 05/20/1999 | WO1999024436A1 1'-[4-[1- (4-fluorophenyl)- 1h-indole-3-yl] -1-butyl]-spiro [isobenzofuran- 1(3h),4'- piperidine] hydrohalogenides |
| 05/20/1999 | WO1999024416A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 05/20/1999 | WO1999024408A1 Heterocyclic compounds having mmp and tnf inhibitory activity |
| 05/20/1999 | WO1999024404A1 Substituted pyridine compounds as anti-inflammatory agents |
| 05/20/1999 | WO1999024043A1 Viscous compositions containing carbon dioxide |
| 05/20/1999 | CA2308358A1 Heterocyclic compounds having mmp and tnf inhibitory activity |
| 05/19/1999 | EP0915826A1 Smooth muscle spasmolytic agents, compositions and methods of use thereof |
| 05/18/1999 | US5905076 Treatment of muscular dystrophy, arthritis, myocardial infarction, alzheimer's disease, bacterial infection, common cold, osteoporosis or cancer metastasis |
| 05/14/1999 | WO1999023092A2 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them |
| 05/14/1999 | WO1999023087A1 Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors |
| 05/14/1999 | WO1999023075A1 Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents |
| 05/14/1999 | WO1999022733A1 Novel metal complexes |
| 05/14/1999 | WO1998051289A3 Monoesters of probucol for the treatment of cardiovascular and inflammatory disease |
| 05/14/1999 | CA2308317A1 Novel metal complexes |
| 05/14/1999 | CA2307905A1 3-aminoalkylamino-2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands |
| 05/14/1999 | CA2307853A1 Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors |
| 05/12/1999 | EP0914432A2 Secreted proteins and polynucleotides encoding them |
| 05/12/1999 | EP0914119A2 Solid oral dosage forms of valsartan |
| 05/12/1999 | EP0735888A4 Purine compositions and methods for administration |
| 05/12/1999 | CN1216472A A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent |
| 05/06/1999 | WO1999021854A1 Bis-quaternary ammonium derivatives as neuromuscular relaxants |
| 05/06/1999 | WO1999021834A1 Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors |
| 05/06/1999 | WO1999021565A1 Nutritional supplement for cerebral metabolic insufficiencies |
| 05/06/1999 | WO1999021562A1 Treatment of female sexual dysfunction |
| 05/06/1999 | WO1999013054A3 Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
| 05/06/1999 | EP0912601A1 Suppression of immune response via inhibition of cathepsin s |
| 05/06/1999 | EP0912518A1 Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| 05/06/1999 | EP0912487A1 Substituted oxobutyric acids as matrix metalloprotease inhibitors |
| 05/06/1999 | CA2306878A1 Bis-quaternary ammonium derivatives as neuromuscular relaxants |
| 05/05/1999 | CN1216043A Substd. benzenesulfonamide derivs as prodrugs of COX-2 inhibitors |
| 04/29/1999 | WO1999020601A1 α-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| 04/29/1999 | CA2305798A1 .alpha.-aryl-n-alkylnitrones and pharmaceutical compositions containing the same |
| 04/28/1999 | EP0910564A1 D-amino acid derived inhibitors of cysteine and serine proteases |
| 04/28/1999 | EP0910378A1 Methods of increasing sphincter competence |
| 04/22/1999 | WO1999019477A1 Cadherin derived growth factor and the application thereof |
| 04/22/1999 | WO1999018987A1 Ligand binding site of rage and uses thereof |
| 04/22/1999 | WO1999018976A1 Therapeutic methods comprising use of a neuregulin |
| 04/22/1999 | WO1999018938A1 Delayed total release gastrointestinal drug delivery system |
| 04/22/1999 | CA2306228A1 Therapeutic methods comprising use of a neuregulin |
| 04/21/1999 | EP0909184A2 Targeted drug delivery using sulfonamide derivatives |
| 04/21/1999 | EP0909171A1 Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 |
| 04/15/1999 | WO1999018193A1 Jnk3 modulators and methods of use |
| 04/15/1999 | WO1999018123A1 Use of neuronal and lymphocytic potassium canal inhibitors for treating neurological diseases of immune origin |
| 04/15/1999 | WO1999018120A1 Deuterated cyclosporine analogs and their use as immunomodulating agents |
| 04/15/1999 | WO1999017775A1 QUINOLINE-CONTAINING α-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS |
| 04/15/1999 | WO1999009054A3 Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders |
| 04/15/1999 | WO1999008708A3 Method and food product for increasing muscle protein and reducing fat in animals |
| 04/15/1999 | WO1998045322A3 Diagnosis method and reagents |